Last reviewed · How we verify

Paronychia — Treatment Landscape & Competitive Intelligence

Paronychia (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Paronychia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Garamycin GENTAMICIN Merck & Co. Aminoglycoside Antibacterial Transient receptor potential cation channel subfamily V member 5 1970-01-01
Gentamicin Gentamicin Sulfate Merck & Co. gentamicin Dihydrofolate reductase 1970-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Merck & Co. · 2 drugs in Paronychia
  2. · 1 drug in Paronychia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Paronychia:

Cite this brief

Drug Landscape (2026). Paronychia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/paronychia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing